Loading
Life sciences · Journal article
Frontiers in Oncology · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Therapies targeting cancer-specific mutations can result in remarkable clinical responses while reducing adverse effects. We describe the use of lorlatinib, a potent oral inhibitor of anaplastic lymphoma kinase (ALK) that crosses the blood brain barrier (BBB), in a case report of two patients with refractory and relapsed ALK+ anaplastic large cell lymphoma (ALK+ ALCL) with central nervous system (CNS) involvement. In both cases, treatment with single agent lorlatinib led to rapid and durable complete remission with tolerable side effects. Furthermore, we also describe a novel application of next generation sequencing to characterize circulating immune receptor DNA sequences associated with ALCL, and tracked the molecular response to therapy with subsequent blood specimens. These cases demonstrate that utilization of an effective targeted therapy against cancer-specific driver mutations that penetrates the BBB can lead to a significant clinical response, and presents clonal tracking for molecular response assessment as a potential approach for further study.